Journal Article
. 2013 Sep; 105(19):1504-11.
doi: 10.1093/jnci/djt244.

Factors predicting late recurrence for estrogen receptor-positive breast cancer

Ivana Sestak 1 Mitch Dowsett  Lila Zabaglo  Elena Lopez-Knowles  Sean Ferree  J Wayne Cowens  Jack Cuzick  
Affiliations
  • PMID: 24029245
  •     16 References
  •     85 citations

Abstract

Background: Adjuvant endocrine therapy beyond 5 years reduces recurrence in patients with estrogen receptor-positive breast cancer. We have previously shown that immunohistochemical markers (IHC4) and two gene expression profile tests (recurrence score [RS] and PAM50 risk of recurrence [ROR]) are associated with time to distant recurrence, and we have now assessed the value of each of these scores and routine clinical variables for predicting outcome, specifically in years 5 to 10.

Methods: We used univariate and multivariable proportional hazards models to determine the prognostic value of all variables and scores (IHC4, RS, ROR) for distant recurrence, separately in years 0 to 5 and specifically for years 5 to 10 for all patients. All statistical tests were two-sided.

Results: Nodal status and tumor size were at least as strong in years 5 to 10 as in years 0 to 5 (nodal status, years 5-10: χ² = 21.72 vs years 0-5: χ² = 11.08, both P < .001; tumor size, years 5-10: χ² = 10.52 vs years 0-5: χ² = 10.82, both P = .001). Ki67 and the overall IHC4 score were the only statistically significant biomarkers related to distant recurrence univariablely in the 5 to 10 year period (χ² = 8.67, χ² = 13.22, respectively). The ROR score was the strongest molecular prognostic factor in the late follow-up period (χ² = 16.29; P < .001), whereas IHC4 (χ² = 7.41) and RS (χ² = 5.55) were only weakly prognostic in this period. Similar results were seen for all subgroups and for all recurrences.

Conclusions: None of the IHC4 markers provided statistically significant prognostic information in years 5 to 10, except for nodal status and tumor size. ROR gave the strongest prognostic information in years 5 to 10. These results may help select patients who could benefit most from hormonal therapy beyond 5 years of treatment.

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick, Ivana Sestak, +5 authors, ATAC/LATTE investigators.
Lancet Oncol, 2010 Nov 23; 11(12). PMID: 21087898
Highly Cited.
Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, +18 authors, NCIC CTG MAP.3 Study Investigators.
N Engl J Med, 2011 Jun 07; 364(25). PMID: 21639806
Highly Cited.
Biologic markers determine both the risk and the timing of recurrence in breast cancer.
Laura J Esserman, Dan H Moore, +11 authors, Christopher C Benz.
Breast Cancer Res Treat, 2011 May 21; 129(2). PMID: 21597921    Free PMC article.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, +36 authors, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Lancet, 2012 Dec 12; 381(9869). PMID: 23219286    Free PMC article.
Highly Cited.
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Tamoxifen for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group.
Cochrane Database Syst Rev, 2001 Nov 09; (1). PMID: 11279694
Systematic Review.
Annual hazard rates of recurrence for breast cancer after primary therapy.
T Saphner, D C Tormey, R Gray.
J Clin Oncol, 1996 Oct 01; 14(10). PMID: 8874335
Highly Cited.
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 May 30; 351(9114). PMID: 9605801
Highly Cited.
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, John F Forbes, +4 authors, Michael Baum.
Lancet Oncol, 2007 Dec 18; 9(1). PMID: 18083636
Highly Cited.
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Mitch Dowsett, Craig Allred, +17 authors, Aman Buzdar.
J Clin Oncol, 2008 Jan 30; 26(7). PMID: 18227529
Highly Cited.
Residual risk of breast cancer recurrence 5 years after adjuvant therapy.
Abenaa M Brewster, Gabriel N Hortobagyi, +8 authors, Francisco J Esteva.
J Natl Cancer Inst, 2008 Aug 13; 100(16). PMID: 18695137    Free PMC article.
Highly Cited.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
An unmet need: tailoring extended adjuvant endocrine therapy.
G Bianchini, L Gianni.
Br J Cancer, 2013 Nov 21; 109(12). PMID: 24253504    Free PMC article.
Genomic profiling in luminal breast cancer.
Oleg Gluz, Daniel Hofmann, +3 authors, Nadia Harbeck.
Breast Care (Basel), 2014 Feb 20; 8(6). PMID: 24550749    Free PMC article.
Review.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Miguel Martin, Jan C Brase, +15 authors, Alvaro Rodriguez-Lescure.
Breast Cancer Res, 2014 Apr 15; 16(2). PMID: 24725534    Free PMC article.
Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases.
Hanna Dillekås, Monica Transeth, +2 authors, Oddbjørn Straume.
Breast Cancer Res Treat, 2014 Jul 21; 146(3). PMID: 25038878    Free PMC article.
Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.
Agnieszka K Witkiewicz, Uthra Balaji, Erik S Knudsen.
Clin Cancer Res, 2014 Jul 23; 20(18). PMID: 25047707    Free PMC article.
Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.
Anieta M Sieuwerts, Maria B Lyng, +6 authors, Henrik J Ditzel.
Mol Oncol, 2014 Aug 02; 8(8). PMID: 25081647    Free PMC article.
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Review.
Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Y Horimoto, A Arakawa, +9 authors, M Saito.
Br J Cancer, 2014 Nov 26; 112(2). PMID: 25422910    Free PMC article.
Biology of breast cancer in young women.
Hatem A Azim, Ann H Partridge.
Breast Cancer Res, 2014 Dec 02; 16(4). PMID: 25436920    Free PMC article.
Highly Cited. Review.
Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer.
Kenjiro Aogi, Takayuki Kadoya, +4 authors, Morihito Okada.
Breast Cancer Res Treat, 2015 Feb 24; 150(1). PMID: 25697596    Free PMC article.
Markers for the identification of late breast cancer recurrence.
Ivana Sestak, Jack Cuzick.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25848913    Free PMC article.
Review.
Developing a new generation of breast cancer clinical gene expression tests.
Zuzana Kos, Torsten O Nielsen.
Breast Cancer Res, 2014 Jan 01; 16(4). PMID: 25928431    Free PMC article.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.
Kathleen Van Asten, An Poppe, +4 authors, Patrick Neven.
Curr Treat Options Oncol, 2015 Jun 03; 16(7). PMID: 26031545
Review.
Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
Yi-Zi Zheng, Lei Wang, Xin Hu, Zhi-Ming Shao.
Oncotarget, 2015 Jun 04; 6(26). PMID: 26036636    Free PMC article.
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Joseph A Sparano, Fengmin Zhao, +7 authors, Nancy E Davidson.
J Clin Oncol, 2015 Jun 17; 33(21). PMID: 26077235    Free PMC article.
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients.
Hideo Shimizu, Yoshiya Horimoto, +14 authors, Mitsue Saito.
Breast Care (Basel), 2015 Jul 22; 10(2). PMID: 26195940    Free PMC article.
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Brett Wallden, James Storhoff, +16 authors, Joel S Parker.
BMC Med Genomics, 2015 Aug 25; 8. PMID: 26297356    Free PMC article.
Highly Cited.
The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial.
Neema Jamshidi, Eric Jonasch, +4 authors, Michael D Kuo.
Eur Radiol, 2015 Nov 13; 26(8). PMID: 26560727
A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis.
Sarah Nechuta, Wendy Y Chen, +7 authors, Xiao Ou Shu.
Int J Cancer, 2015 Nov 26; 138(9). PMID: 26606746    Free PMC article.
Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*.
Genet Med, 2015 Dec 19; 18(8). PMID: 26681310
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.
Marco Colleoni, Zhuoxin Sun, +8 authors, Aron Goldhirsch.
J Clin Oncol, 2016 Jan 21; 34(9). PMID: 26786933    Free PMC article.
Highly Cited.
Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.
Mai Tomiguchi, Yutaka Yamamoto, +8 authors, Hirotaka Iwase.
Cancer Sci, 2016 Jan 24; 107(4). PMID: 26801869    Free PMC article.
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Miguel Martin, Jan C Brase, +15 authors, Alvaro Rodriguez-Lescure.
Breast Cancer Res Treat, 2016 Feb 26; 156(1). PMID: 26909792    Free PMC article.
Late Axillary Recurrence After Negative Sentinel Lymph Node Biopsy is Uncommon.
Cindy Matsen, Kristine Villegas, +5 authors, Alexandra Heerdt.
Ann Surg Oncol, 2016 Mar 10; 23(8). PMID: 26957506    Free PMC article.
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
Se Hyun Kim, Kyung Hae Jung, +16 authors, Jee Hyun Kim.
Cancer Res Treat, 2016 Oct 19; 48(4). PMID: 27034147    Free PMC article.
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
Norman Wolmark, Eleftherios P Mamounas, +6 authors, Soonmyung Paik.
J Clin Oncol, 2016 May 25; 34(20). PMID: 27217450    Free PMC article.
Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.
Eun-Shin Lee, Wonshik Han, +9 authors, Eun Sook Lee.
BMC Cancer, 2016 Jul 09; 16. PMID: 27388210    Free PMC article.
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Richard Buus, Ivana Sestak, +7 authors, Mitch Dowsett.
J Natl Cancer Inst, 2016 Jul 13; 108(11). PMID: 27400969    Free PMC article.
Highly Cited.
Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.
Pattaraporn Wangchinda, Suthinee Ithimakin.
World J Surg Oncol, 2016 Aug 26; 14(1). PMID: 27557635    Free PMC article.
Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets.
Pooja Ghatalia, Eddy S Yang, +12 authors, Guru Sonpavde.
PLoS One, 2016 Aug 31; 11(8). PMID: 27574806    Free PMC article.
Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy.
Birte Hellwig, Katrin Madjar, +11 authors, Jörg Rahnenführer.
PLoS One, 2016 Dec 08; 11(12). PMID: 27926932    Free PMC article.
The prevalence and clinicopathological features of breast cancer patients with hepatitis B virus infection in China.
He Wu, Chunxia Zhao, +9 authors, Ling-Quan Kong.
Oncotarget, 2017 Feb 18; 8(11). PMID: 28212549    Free PMC article.
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Aranzazu Fernandez-Martinez, Tomás Pascual, +30 authors, Miguel Martin.
Oncotarget, 2017 Apr 21; 8(13). PMID: 28423537    Free PMC article.
Long-Term Follow-Up of the Intergroup Exemestane Study.
James P Morden, Isabel Alvarez, +18 authors, R Charles Coombes.
J Clin Oncol, 2017 May 04; 35(22). PMID: 28467729    Free PMC article.
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.
Terri P McVeigh, Michael J Kerin.
Breast Cancer (Dove Med Press), 2017 Jun 16; 9. PMID: 28615971    Free PMC article.
Review.
Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.
Karin Elebro, Pär-Ola Bendahl, Helena Jernström, Signe Borgquist.
Breast Cancer Res Treat, 2017 Jun 24; 165(3). PMID: 28643022    Free PMC article.
Body mass index, waist-to-hip ratio and late outcomes: a report from the Shanghai Breast Cancer Survival Study.
Minlu Zhang, Hui Cai, +4 authors, Ying Zheng.
Sci Rep, 2017 Aug 03; 7(1). PMID: 28765555    Free PMC article.
Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy.
Ivana Sestak.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785181    Free PMC article.
Review.
Prognostic immune-related gene models for breast cancer: a pooled analysis.
Jianli Zhao, Ying Wang, +6 authors, Kai Chen.
Onco Targets Ther, 2017 Oct 06; 10. PMID: 28979134    Free PMC article.
ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy.
Fangbin Song, Jianbing Zhang, +6 authors, Junming Xu.
Onco Targets Ther, 2017 Oct 19; 10. PMID: 29042797    Free PMC article.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
Clinical utility of multigene profiling assays in early-stage breast cancer.
M C Chang, L H Souter, +6 authors, Molecular Oncology Advisory Committee.
Curr Oncol, 2017 Nov 02; 24(5). PMID: 29089811    Free PMC article.
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, +9 authors, EBCTCG.
N Engl J Med, 2017 Nov 09; 377(19). PMID: 29117498    Free PMC article.
Highly Cited.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
Linda S Lindström, Christina Yau, +19 authors, STO Trialists Group.
J Natl Cancer Inst, 2018 Jan 24; 110(7). PMID: 29361175    Free PMC article.
Stanniocalcin Expression as a Predictor of Late Breast Cancer Recurrence.
Kristen D Brantley, Anders Kjærsgaard, +5 authors, Timothy L Lash.
Cancer Epidemiol Biomarkers Prev, 2018 Mar 30; 27(6). PMID: 29593009    Free PMC article.
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Mitch Dowsett, Ivana Sestak, +5 authors, Jack Cuzick.
J Clin Oncol, 2018 Apr 21; 36(19). PMID: 29676944    Free PMC article.
Optimal management of luminal breast cancer: how much endocrine therapy is long enough?
Elisabetta Munzone, Marco Colleoni.
Ther Adv Med Oncol, 2018 Jul 07; 10. PMID: 29977350    Free PMC article.
Review.
SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment.
Yu-Hsiang Huang, Pei-Yi Chu, +8 authors, Chun-Yu Liu.
J Clin Med, 2018 Aug 30; 7(9). PMID: 30154367    Free PMC article.
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Richard Buus, Belinda Yeo, +7 authors, Mitch Dowsett.
Breast Cancer Res, 2018 Sep 06; 20(1). PMID: 30180877    Free PMC article.
Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis.
Shuning Ding, Jiayi Wu, +6 authors, Li Zhu.
Oncologist, 2019 Apr 26; 24(11). PMID: 31019021    Free PMC article.
A prognostic 10-lncRNA expression signature for predicting the risk of tumour recurrence in breast cancer patients.
Jianing Tang, Jiangbo Ren, +6 authors, Gaosong Wu.
J Cell Mol Med, 2019 Aug 21; 23(10). PMID: 31429520    Free PMC article.
Panoptic View of Prognostic Models for Personalized Breast Cancer Management.
Geetanjali Saini, Karuna Mittal, +3 authors, Ritu Aneja.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500225    Free PMC article.
Review.
Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen.
Soo Yeon Baek, Ji Yeong Kwon, +12 authors, Jong Won Lee.
J Breast Cancer, 2019 Oct 11; 22(3). PMID: 31598339    Free PMC article.
Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor.
Takashi Takeshita, Li Yan, +2 authors, Kazuaki Takabe.
Sci Rep, 2019 Nov 16; 9(1). PMID: 31729458    Free PMC article.
Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China.
Yuqin Ding, Kaijing Ding, +6 authors, Xiaowen Ding.
Oncol Lett, 2019 Dec 07; 18(6). PMID: 31807179    Free PMC article.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
Review.
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
Fabio Conforti, Laura Pala, +12 authors, Aron Goldhirsch.
Breast Cancer Res, 2020 Jan 01; 21(1). PMID: 31888717    Free PMC article.
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Andreas Heindl, Ivana Sestak, +3 authors, Yinyin Yuan.
J Natl Cancer Inst, 2017 Sep 02; 110(2). PMID: 28859291    Free PMC article.
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Joseph Sparano, Anne O'Neill, +5 authors, Kathy D Miller.
JAMA Oncol, 2018 Jul 29; 4(12). PMID: 30054636    Free PMC article.
Highly Cited.
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
Oscar M Rueda, Stephen-John Sammut, +21 authors, Christina Curtis.
Nature, 2019 Mar 15; 567(7748). PMID: 30867590    Free PMC article.
Highly Cited.
DEAD-box RNA Helicase 39 Promotes Invasiveness and Chemoresistance of ER-positive Breast Cancer.
Xiudi Wang, Peipei Li, +4 authors, Jiajin Lin.
J Cancer, 2020 Mar 21; 11(7). PMID: 32194796    Free PMC article.
Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value.
Changjun Wang, Chang Chen, +10 authors, Qiang Sun.
Sci Rep, 2020 Mar 15; 10(1). PMID: 32170181    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
An estrogen receptor (ER)-related signature in predicting prognosis of ER-positive breast cancer following endocrine treatment.
Jianing Tang, Qiuxia Cui, +3 authors, Gaosong Wu.
J Cell Mol Med, 2019 May 28; 23(8). PMID: 31124293    Free PMC article.
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer.
Steven A Buechler, Kathryn P Gray, +7 authors, Meredith M Regan.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337480    Free PMC article.
Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
Jiani Zheng, Jingxun Wu, +3 authors, Feng Ye.
PLoS One, 2020 Jun 05; 15(6). PMID: 32497134    Free PMC article.
Systematic Review.
DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer.
Lei Lei, Xiao-Jia Wang, +2 authors, Yunyun Zhou.
Front Oncol, 2020 Jun 13; 10. PMID: 32528885    Free PMC article.
Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-positive, HER2-negative Breast Cancer Patients.
Claudia Mazo, Stephen Barron, Catherine Mooney, William M Gallagher.
Cancers (Basel), 2020 May 07; 12(5). PMID: 32369904    Free PMC article.
Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.
Alex J Gooding, William P Schiemann.
Mol Cancer Res, 2020 Jun 07; 18(9). PMID: 32503922    Free PMC article.
Review.
Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training.
John M S Bartlett, Jane Bayani, +8 authors, OPTIMA Trial Management Group.
PLoS One, 2020 Sep 04; 15(9). PMID: 32881987    Free PMC article.
Prognostic Factors of Local-Regional Recurrence in Patients with Operable Breast Cancer in Asia: A Meta-Analysis.
Wirsma Arif Harahap, Ricvan Dana Nindrea.
Open Access Maced J Med Sci, 2019 Mar 22; 7(4). PMID: 30894935    Free PMC article.
Review.
The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity.
Lin He, Yang Lv, Yuhua Song, Biyuan Zhang.
Cancer Manag Res, 2019 Jul 16; 11. PMID: 31303789    Free PMC article.
Review.
Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer.
Ming Fan, Pingping Xia, +2 authors, Lihua Li.
Nat Commun, 2020 Sep 27; 11(1). PMID: 32978398    Free PMC article.
Individualized Prediction of Survival by a 10-Long Non-coding RNA-Based Prognostic Model for Patients With Breast Cancer.
Xuemei Yang, Juan Li, +9 authors, Chuanxin Wang.
Front Oncol, 2020 Nov 17; 10. PMID: 33194577    Free PMC article.
Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer.
Amye J Tevaarwerk, Kari B Wisinski, Ruth M O'Regan.
J Oncol Pract, 2016 Nov 20; 12(11). PMID: 27858538    Free PMC article.
Review.
5-Year Survival Rates and Prognostic Factors in Patients with Synchronus and Metachronus Breast Cancer from 2010 to 2015
Arash Sarveazad, Asrin Babahajian, Jebreil Shamseddin, Mansour Bahardoust.
Asian Pac J Cancer Prev, 2018 Dec 26; 19(12). PMID: 30583674    Free PMC article.
Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study.
Salvatore Pece, Davide Disalvatore, +8 authors, Pier Paolo Di Fiore.
EBioMedicine, 2019 Mar 09; 42. PMID: 30846393    Free PMC article.
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication.
Takayuki Ueno, Shigehira Saji, +11 authors, Masakazu Toi.
ESMO Open, 2019 Apr 10; 4(1). PMID: 30962956    Free PMC article.
A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy.
Vasily Giannakeas, Steven A Narod.
Breast Cancer Res Treat, 2019 Jul 03; 177(3). PMID: 31264063    Free PMC article.
The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Wakako Tajiri, Hideki Ijichi, +8 authors, Eriko Tokunaga.
Breast Cancer, 2020 Jul 01; 28(1). PMID: 32601800    Free PMC article.
Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
Serafin Morales Murillo, Ariadna Gasol Cudos, +6 authors, Antonieta Salud Salvia.
Breast, 2021 Feb 19; 56. PMID: 33601299    Free PMC article.
Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea.
Jun-Hee Lee, Se Kyung Lee, +5 authors, Jai Min Ryu.
Front Oncol, 2021 Jul 10; 11. PMID: 34239805    Free PMC article.
Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study.
John M S Bartlett, Jane Bayani, +14 authors, Daniel Rea.
NPJ Breast Cancer, 2021 Jul 10; 7(1). PMID: 34238931    Free PMC article.